A detailed history of Rhumbline Advisers transactions in Bionomics Limited stock. As of the latest transaction made, Rhumbline Advisers holds 8,300 shares of BNOX stock, worth $2,407. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,300
Previous 2,195 278.13%
Holding current value
$2,407
Previous $1,000 200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.44 - $0.84 $2,686 - $5,128
6,105 Added 278.13%
8,300 $3,000
Q2 2024

Aug 01, 2024

BUY
$0.69 - $1.2 $614 - $1,068
890 Added 68.2%
2,195 $1,000
Q1 2024

May 09, 2024

BUY
$0.89 - $1.38 $712 - $1,104
800 Added 158.42%
1,305 $1,000
Q3 2023

Nov 09, 2023

BUY
$0.95 - $3.37 $479 - $1,701
505 New
505 $1,000

Others Institutions Holding BNOX

About BIONOMICS LIMITED


  • Ticker BNOX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,518,620
  • Market Cap $2.18M
  • Description
  • Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has ...
More about BNOX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.